Newron Pharmaceuticals Kicks Off Late-stage Schizophrenia Therapy Study in US

01:46 AM EST, 12/08/2025 (MT Newswires) -- Newron Pharmaceuticals (NWRN.SW) launched a late-stage study in the US to evaluate evenamide as an add-on therapy for treatment-resistant schizophrenia patients. The Enigma-TRS 2 phase 3 program will enroll at least 400 patients in the randomized, double-blind, placebo-controlled 12-week clinical study to evaluate the efficacy, safety, and tolerability of evenamide 15 milligrams twice daily as an add-on therapy to current antipsychotics, compared with placebo, the biopharmaceutical company said Monday. The Enigma-TRS phase 3 program consists of two parts, with Enigma-TRS 1 enrolling at least 600 patients in a one-year, double-blind, placebo-controlled study to evaluate the efficacy, tolerability, and safety of 15 mg and 30 mg doses taken twice daily. Topline results from the Enigma-TRS 2 are expected in the fourth quarter of 2026.